The US FDA in the Wake of Vioxx - Overcautious or Showing Due Care?
This article was originally published in SRA
Executive Summary
People are lining up to accuse the US Food and Drug Administration (FDA) of having become more conservative in its assessment of new pharmaceuticals in the light of recent high-profile safety controversies.